Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 9/20 | 0.44 |
| ▸ | CDK2 | P24941 | 9/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093045 | 0.94 | IKBKB (0.40) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL4092769 | 0.90 | IKBKB (0.37) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL3295498 | 0.87 | IKBKB (0.41) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL13392156 | 0.86 | IKBKB (0.43) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL3301843 | 0.86 | CDK1 (0.45) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL3301250 | 0.86 | CDK1 (0.45) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL3301336 | 0.86 | IKBKB (0.45) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL3295552 | 0.86 | IKBKB (0.44) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL3302166 | 0.86 | CDK1 (0.44) | CDK1CDK2IKBKBCHUKIKBKG | |
| SCHEMBL3299104 | 0.86 | IKBKB (0.46) | CDK1CDK2IKBKBCHUKIKBKG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | claimed |
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | CHUK, IKBKB, IKBKE | CDK1 15/4885CDK2 8/4885IKBKB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.